Articles tagged with: Revlimid

News»

[ by | Dec 12, 2011 4:21 pm | 2 Comments ]
ASH 2011 Multiple Myeloma Update – Day Two

Results from a number of multiple myeloma studies were presented yesterday during the second day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego.

Predicting Response To Immunomodulatory Drugs

During an oral presentation and a poster presentation yesterday, researchers discussed the role of the protein cereblon in the treatment of myeloma.  Results from one study (abstract) in myeloma cell lines suggested that cereblon plays a key role in whether multiple myeloma patients respond to the immunomodulatory drugs Revlimid (lenalidomide) and pomalidomide.  Another study …

Read the full story »

News»

[ by | Dec 6, 2011 12:22 pm | 4 Comments ]
Initial Treatment With Cyclophosphamide, Velcade, And Dexamethasone Compares Favorably In Terms Of Response Rates And Side Effects

Results of a recent study show that newly diagnosed multiple myeloma patients initially treated with a combination of cyclophosphamide, Velcade, and dexamethasone have better response rates and less severe side effects than patients treated with Revlimid-dexamethasone or cyclophosphamide-Revlimid-dexamethasone.

The survival outcomes for the patients treated with cyclophosphamide, Velcade, and dexamethasone also are promising.

However, the difference in survival rates between the three treatment regimens is not statistically significant.

This is partly because “the numbers [of patients in the study] were too small to show differences in survival,” explained Dr. Craig Reeder …

Read the full story »

News»

[ by | Nov 11, 2011 1:27 pm | Comments Off ]
New Review Looks At Treatment Strategies For Relapsed And Refractory Multiple Myeloma Patients – Part 2: Treatment Strategies At Relapse

A group of French myeloma specialists recently published a review of treatment strategies for multiple myeloma patients who have relapsed or become resistant to previous therapies.

This Beacon article, the second in a two-part series, summarizes the review’s insights into issues that need to be considered when choosing among relapse treatment options

Part 1 summarizes the review’s perspectives on the use of novel agents in the treatment of relapsed and refractory myeloma.  

According to the authors of the review, the goal at relapse is to select a treatment regimen …

Read the full story »

News»

[ by and | Nov 9, 2011 7:29 pm | Comments Off ]
New Review Looks At Treatment Strategies For Relapsed And Refractory Multiple Myeloma – Part 1: Retreatment With Novel Agents

A group of French myeloma specialists recently published a review of treatment strategies for multiple myeloma patients who have relapsed or become resistant to previous therapies.

This Beacon article, the first in a two-part series, summarizes the review’s perspectives on the use of novel agents in the treatment of relapsed and refractory myeloma.  

A second Beacon article will look at the review’s insights into issues that need to be considered when choosing among relapse treatment options.

The authors of the recent review begin their discussion by noting how use …

Read the full story »

News»

[ by | Oct 31, 2011 2:33 pm | 5 Comments ]
Study Finds Early And Delayed Stem Cell Transplants Have Comparable Efficacy In Newly Diagnosed Multiple Myeloma Patients

Results of a recent analysis suggest that newly diagnosed multiple myeloma patients receiving Revlimid or thalidomide as initial therapy have similar prognoses regardless of whether they receive an early stem cell transplant or delay the transplant and continue their initial treatment.

Specifically, the authors of the analysis found that myeloma patients who received a stem cell transplant early in the course of their disease had a comparable survival rate and time to disease progression as patients who continued Revlimid (lenalidomide) or thalidomide (Thalomid) as initial therapy and intended …

Read the full story »